Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albiglutide in Pediatric Type 2 Diabetes
NCT03015519Phase 3Withdrawn
- Sponsor
- GSK
- Start
- Aug 2017
- Primary completion
- Apr 2020
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of albiglutide in type 2 diabetes mellitus (T2DM), sponsored by GSK. Planned start Aug 2017; status: withdrawn.
02
Drugs
albiglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03015519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03015519.